Which of the following drug is used curvently for the prophylaxis of non infectious uveitis in LUMINATE programme
**Core Concept**
The LUMINATE programme is focused on the treatment and prevention of non-infectious uveitis, a type of inflammation inside the eye. The programme is investigating novel treatments that can effectively manage this condition.
**Why the Correct Answer is Right**
The LUMINATE programme specifically evaluated the efficacy of a drug called brolucizumab in preventing non-infectious uveitis. Brolucizumab is a humanized single-chain antibody fragment that targets vascular endothelial growth factor A (VEGF-A), a key protein involved in angiogenesis and inflammation. By inhibiting VEGF-A, brolucizumab can reduce inflammation and prevent the progression of uveitis. The programme demonstrated the safety and efficacy of brolucizumab in preventing non-infectious uveitis.
**Why Each Wrong Option is Incorrect**
**Option A:** Not relevant to the LUMINATE programme.
**Option B:** Not a drug used for the prophylaxis of non-infectious uveitis.
**Option C:** Not evaluated in the LUMINATE programme for this indication.
**Clinical Pearl / High-Yield Fact**
Brolucizumab is a novel anti-VEGF therapy that has shown promise in preventing non-infectious uveitis. This treatment option may offer a new hope for patients with this condition, reducing the risk of inflammation and preserving vision.
**Correct Answer: A. Brolucizumab**